1. Introduction

Endocrine disorders on the first day of life are medical emergencies. Early recognition is critical to prevent metabolic collapse (hypoglycemia, shock), incorrect gender assignment, or long-term neurodevelopmental sequelae. Diagnosis primarily relies on recognizing clinical “red flags” before screening results are available.

2. Presentation A: Ambiguous Genitalia (DSD)

The most common endocrine cause for ambiguous genitalia is Congenital Adrenal Hyperplasia (CAH).

  • Congenital Adrenal Hyperplasia (CAH):
    • Pathophysiology: 21-hydroxylase deficiency (90%) leads to cortisol deficiency and androgen excess.
    • Day 1 Findings:
      • Females (46,XX): Virilization, clitoromegaly, labial fusion, single perineal opening (Prader staging).
      • Males (46,XY): Usually normal genitalia (diagnosis missed on Day 1 unless family history is known), or hyperpigmentation of scrotum.
    • Immediate Action: Do not assign gender. Check electrolytes (baseline) and 17-OHP.
  • Androgen Insensitivity / Biosynthesis Defects:
    • Males (46,XY): Undervirilization, micropenis, or hypospadias.

3. Presentation B: Refractory Hypoglycemia

Hypoglycemia on Day 1 that requires high Glucose Infusion Rates (GIR > 8-10 mg/kg/min) suggests an endocrine etiology.

  • Congenital Hyperinsulinism (CHI):
    • Clinical: Macrosomia, Large for Gestational Age (LGA), “hairy ear” pinnae.
    • Mechanism: Unregulated insulin secretion causing severe, persistent hypoglycemia.
  • Congenital Hypopituitarism (MPH Deficiency):
    • Clinical: Normal size or slight growth restriction.
    • Triad: Hypoglycemia + Micropenis + Midline defects (cleft lip/palate, optic nerve hypoplasia).
    • Mechanism: Deficiency of Growth Hormone (GH) and ACTH (Cortisol).
  • Infant of Diabetic Mother (IDM):
    • Transient hyperinsulinism due to maternal hyperglycemia.

4. Presentation C: Physical Stigmata & Dysmorphism

Certain syndromes with endocrine components present with visible signs on Day 1.

  • Congenital Hypothyroidism (Sporadic/Athyrosis):
    • Usually asymptomatic on Day 1, but severe cases may show:
    • Large posterior fontanelle (> 0.5 cm).
    • Macroglossia.
    • Umbilical hernia.
    • Hypothermia/Mottling.
  • Neonatal Thyrotoxicosis:
    • History: Mother with Graves’ disease (TSH receptor antibodies cross placenta).
    • Signs: Irritability, tachycardia (>180 bpm), prominent eyes, goiter, frontal bossing.
  • Turner Syndrome (45,XO):
    • Presents with pedal lymphedema (puffy feet) and redundant nuchal skin (web neck).
  • DiGeorge Syndrome (22q11.2 deletion):
    • Presents with hypocalcemic seizures (Hypoparathyroidism) + Cardiac defects (Truncus/TOF).

5. Presentation D: Electrolyte Abnormalities

  • Hypocalcemia: Early onset (< 72 hrs) seen in DiGeorge syndrome or maternal hyperparathyroidism.
  • Hyponatremia: Rare on Day 1 in CAH (salt-wasting usually starts Day 5-10), but may be seen in severe adrenal hypoplasia or hemorrhage (Waterhouse-Friderichsen).

6. Diagnostic Work-up: “The Critical Sample”

If a neonate presents with hypoglycemia or ambiguous genitalia, blood samples must be drawn during the acute event (before correcting glucose if possible, or immediately after).

A. Hypoglycemia Panel (Critical Sample):

  • Serum Glucose (confirm low value).
  • Serum Insulin & C-peptide (detect Hyperinsulinism).
  • Serum Cortisol & Growth Hormone (detect Hypopituitarism).
  • Free Fatty Acids & Ketones (Ketones are low in hyperinsulinism).

B. Ambiguous Genitalia Panel:

  • Karyotype / FISH for Y chromosome (rapid).
  • 17-Hydroxyprogesterone (17-OHP).
  • Testosterone, LH, FSH.
  • Ultrasound Abdomen (to look for uterus/gonads).

C. Thyroid Profile: T3, T4, TSH (on cord blood or venous sample).

7. Management Principles

  1. Stabilize Glucose: IV Dextrose bolus (2ml/kg of 10%) followed by high GIR infusion.
  2. Rescue Steroids: If cortisol deficiency (Hypopituitarism/CAH) is suspected, give Hydrocortisone after drawing the sample.
  3. Correct Electrolytes: Calcium gluconate for hypocalcemic seizures.
  4. Counseling: Defer naming/gender assignment in ambiguous genitalia cases until karyotype is confirmed.